Recent

% | $
Quotes you view appear here for quick access.

BioLife Solutions, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • CJL72 CJL72 Jun 26, 2011 4:38 AM Flag

    What gives? The market makers are

    BLFS: BioLife Solutions;

    @ 6 Cents; and Estimated For Sale Position of 10M; Per Equity, with Cash Flow Change of (136K) Isolated; Cash is almost nonexistent.

    Report Category, Notes, Report, Price, , Metric, , Weight, , Primary Weight Adj Trading Metric, ,Year / Desig, DAY; Weight Adj Price.

    20. Accumulated Deficit: (52) ,M 10-K. 0.06 , (0.0803) , 1.33 , (0.1071) ,June-24, 0.08

    21.Cash Reduction per CF Statement: (0.136) ,M Cash Change (136K): 0.06 , (30.741) , 1.33 , (40.99) ,June-24, 0.08

    22. Paid in Equity, 43 ,M 10-K. 0.06 , 0.10 , 1.33 , 0.1308 ,June-24, 0.08

    23. Other Equity, 0.00 ,M 10-K. 0.06 , 0.00 , 1.33 , 0 ,June-24, 0.08

    24. Common Stock Amount, 0.07 ,M 10-K. 0.06 , 60 , 1.33 , 80 ,June-24, 0.08

    Sum Trading At: ,Primary Metric per Equity / Cash Flow Line Item.: ($9.548,912) M, 29.3 ,Metric Weighted per Price Range / Change, 6.66_4_304 ,Combined Weight Adj Trade Metric, 38.99_22 ,for -($1.4)M Market Cap, for, (0.02) off .08;

    Forward Estimate:

    Equity $$MM: (10)
    MinRetGrowth: 0.09
    MinRetInv: 0.05
    Weighted Cost of Capital: 81.785%
    Estimated Local Continuing Value, Buyout in $$M: 10.607
    Estimated Factor NOT LOCAL in $$M: 0.200136
    Estimated ContinuingValue: Annual Sales / Top Line Revenue, Desired / Avg per Buyer$$M: 2.122749
    Est Buyout Price : 0.1403_53
    0.03, ,Annual Sales Factor Forward.
    4.607_12_22, ,Price To.
    4.498 Year Turnover Period;
    Year End 2010 Sales 2M;

    Current Range: .06 to .10 [+ or -]

    Quote:Enter BLFS and Get Info @

    http://otcbb.com/asp/Info_Center.asp

    Profile:
    Founded in 1998, with the initial development of its intellectual property base in 1992, BioLife Solutions develops, manufactures, and markets patented hypothermic storage/transport and cryopreservation (freeze) products for cells, tissues, and organs, and also performs contract media manufacturing and contract research and development.
    The Company's proprietary HypoThermosol and CryoStor platform of biopreservation products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing.
    BioLife's GMP products are serum-free and protein-free, fully defined, and pre-formulated to reduce preservation-induced, delayed-onset cell damage and death.

    Website:
    http://www.biolifesolutions.com

    Headlines:
    http://finance.yahoo.com/q/h?s=BLFS.OB+Headlines

    I like the company; Looking for 3.75 to 4.75 Cents with Volume...[10Q Equity @ (10.100405M)
    and there could be a merger or acquirer transaction;ie;Still Trade As BLFS;
    [Speculation per buyout, but Private Equity Buyouts have been doing rather well lately with companies such as BLFS;]

    2006:_14.75 Cents;

    Do not own Shares; Review the Company;

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
BLFS
1.67-0.0300(-1.76%)Mar 26 4:00 PMEDT